非类固醇抗炎药物和口腔癌的风险:一个嵌套的病例控制研究
J Sudbø1, J J Lee, S M Lippman
1Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway. jon.sudbo@rh.uio.no
Lancet (London, England)
|October 18, 2005
概括
非类固醇抗炎药物 (NSAIDs) 可能会降低口腔癌的风险,特别是在吸烟者中. 然而,长期使用NSAID与更高的心血管死亡风险有关,需要仔细评估风险和益处.
科学领域:
- 在瘤学瘤学.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非类固醇抗炎药物 (NSAIDs) 在预防癌症方面具有潜力,但具有心血管风险.
- 使用NSAID与口腔癌发病率或死亡率之间的关联仍然不完全理解.
研究的目的:
- 调查NSAID使用与口腔癌发病率之间的关系.
- 检查NSAID使用对整体和心血管死亡率的影响.
主要方法:
- 通过使用来自挪威队列 (CONOR) 数据库的数据进行了嵌套病例控制研究.
- 患有口腔癌的个体和匹配的对照被从重度吸烟者 (≥15包年) 中选择.
- 分析了与口腔癌诊断和死亡结果相关的NSAID和类药物使用 (至少6个月).
主要成果:
- 使用NSAID与明显降低口腔癌的风险有关 (HR 0.47,P<0.0001),即使在活跃吸烟者中也是如此.
- 长期使用NSAID与心血管疾病相关死亡风险增加相关 (HR2.06,P=0.001).
- 青的使用与口腔癌风险或心血管死亡率没有显著的关联.
结论:
- 长期使用NSAID可以降低口腔癌的发病率,但会增加心血管疾病死亡风险.
- 在考虑长期使用NSAID治疗时,进行彻底的风险效益分析至关重要.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...


